Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy.

doi:10.1016/j.ymthe.2021.02.021

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy.

Molecular therapy : the journal of the American Society of Gene Therapy - 2 Jun 2021

Reschke Cristina R, Silva Luiz F A, Vangoor Vamshidhar R, Rosso Massimo, David Bastian, Cavanagh Brenton L, Connolly Niamh M C, Brennan Gary P, Sanz-Rodriguez Amaya, Mooney Catherine, Batool Aasia, Greene Chris, Brennan Marian, Conroy Ronan M, Rüber Theodor, Prehn Jochen H M, Campbell Matthew, Pasterkamp R Jeroen, Henshall David C

Abstract excerpt

Oligonucleotide therapies offer precision treatments for a variety of neurological diseases, including epilepsy, but their deployment is hampered by the blood-brain barrier (BBB). Previous studies showed that intracerebroventricular injection of an antisense oligonucleotide (antagomir) targeting microRNA-134 (Ant-134) reduced evoked and spontaneous seizures in animal models of epilepsy. In this study, we used...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood-Brain Barrier

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Disease Susceptibility

Share to Epilepsy

Share to Gene Silencing

Share to Gene Transfer Techniques

Share to Genetic Therapy

Share to RNA Interference

Source

Open in PubMed Open full text

Identifiers

PMID: 33609732
DOI: 10.1016/j.ymthe.2021.02.021
PMCID: PMC8178478

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy.PMID 33609732Read ↗

Circulating microRNAs and isomiRs as biomarkers for the initial insult and epileptogenesis in four experimental epilepsy models: The EPITARGET studySemantic proximity Read ↗

Antisense oligonucleotide therapy for <i>KCNT1</i> encephalopathySemantic proximity Read ↗

Brain cell-specific origin of circulating microRNA biomarkers in experimental temporal lobe epilepsySemantic proximity Read ↗

GluK2 is a target for gene therapy in drug-resistant Temporal Lobe EpilepsySemantic proximity Read ↗

Antisense oligonucleotide therapy for KCNT1 encephalopathySemantic proximity Read ↗

Lipid-siRNA conjugate accesses a perivascular transport mechanism and achieves widespread and durable knockdown in the central nervous systemSemantic proximity Read ↗

MicroRNA inhibition using antimiRs in acute human brain tissue sectionsSemantic proximity Read ↗

Selective targeting of Scn8a prevents seizure development in a mouse model of mesial temporal lobe epilepsy.Semantic proximity Read ↗

A novel AAV9-dual microRNA-vector targeting GRIK2 in the hippocampus as a treatment for mesial temporal lobe epilepsySemantic proximity Read ↗

Noninvasive Control of Seizure Threshold with Acoustically Targeted ChemogeneticsSemantic proximity Read ↗

High concordance between hippocampal transcriptome of the intraamygdala kainic acid model and human temporal lobe epilepsySemantic proximity Read ↗

Silencing MicroRNA-134 Alleviates Hippocampal Damage and Occurrence of Spontaneous Seizures After Intraventricular Kainic Acid-Induced Status Epilepticus in RatsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.